These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34323910)

  • 1. Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression.
    Wang CS; Chang CH; Tzeng TY; Lin AM; Lo YL
    Nanoscale Horiz; 2021 Sep; 6(9):729-743. PubMed ID: 34323910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
    Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH
    Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
    Lo YL; Lin HC; Tseng WH
    Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
    Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
    Yi K; Kong H; Zheng C; Zhuo C; Jin Y; Zhong Q; Mintz RL; Ju E; Wang H; Lv S; Lao YH; Tao Y; Li M
    Biomaterials; 2023 Nov; 302():122349. PubMed ID: 37844429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing.
    Sun D; Sun Z; Jiang H; Vaidya AM; Xin R; Ayat NR; Schilb AL; Qiao PL; Han Z; Naderi A; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):667-678. PubMed ID: 30582790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Signalling Pathways Regulated by GPRC5B in β-Cells by CRISPR-Cas9-Mediated Genome Editing.
    Atanes P; Ruz-Maldonado I; Hawkes R; Liu B; Persaud SJ; Amisten S
    Cell Physiol Biochem; 2018; 45(2):656-666. PubMed ID: 29408822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.
    Koo T; Yoon AR; Cho HY; Bae S; Yun CO; Kim JS
    Nucleic Acids Res; 2017 Jul; 45(13):7897-7908. PubMed ID: 28575452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A carrier-free multiplexed gene editing system applicable for suspension cells.
    Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
    Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death.
    Tu K; Deng H; Kong L; Wang Y; Yang T; Hu Q; Hu M; Yang C; Zhang Z
    ACS Appl Mater Interfaces; 2020 Apr; 12(14):16018-16030. PubMed ID: 32192326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
    Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
    ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.
    van Hees M; Slott S; Hansen AH; Kim HS; Ji HP; Astakhova K
    Mol Ther; 2022 Jan; 30(1):32-46. PubMed ID: 34091053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
    Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
    PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer.
    Li M; Xie H; Liu Y; Xia C; Cun X; Long Y; Chen X; Deng M; Guo R; Zhang Z; He Q
    J Control Release; 2019 Jun; 304():204-215. PubMed ID: 31100311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
    Rosenblum D; Gutkin A; Kedmi R; Ramishetti S; Veiga N; Jacobi AM; Schubert MS; Friedmann-Morvinski D; Cohen ZR; Behlke MA; Lieberman J; Peer D
    Sci Adv; 2020 Nov; 6(47):. PubMed ID: 33208369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrion-Directed Nanoparticles Loaded with a Natural Compound and a microRNA for Promoting Cancer Cell Death via the Modulation of Tumor Metabolism and Mitochondrial Dynamics.
    Lo YL; Wang CS; Chen YC; Wang TY; Chang YH; Chen CJ; Yang CP
    Pharmaceutics; 2020 Aug; 12(8):. PubMed ID: 32796618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.